By Mill Chart
Last update: Oct 13, 2023
Our stock screener has spotted BRISTOL-MYERS SQUIBB CO (NYSE:BMY) as an undervalued stock with solid fundamentals. NYSE:BMY shows decent health and profitability. At the same time it remains remains attractively priced. We'll dive into each aspect below.
ChartMill employs its own Valuation Rating system for all stocks. This score, ranging from 0 to 10, is determined by evaluating different valuation factors, including price to earnings and free cash flow, both in absolute terms and relative to the market and industry. NYSE:BMY has earned a 8 for valuation:
ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NYSE:BMY was assigned a score of 8 for profitability:
ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NYSE:BMY scores a 5 out of 10:
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NYSE:BMY was assigned a score of 4 for growth:
More Decent Value stocks can be found in our Decent Value screener.
Our latest full fundamental report of BMY contains the most current fundamental analsysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
BRISTOL-MYERS SQUIBB CO
NYSE:BMY (4/19/2024, 7:04:00 PM)
After market: 48.93 0 (0%)48.93
+0.63 (+1.3%)
These stocks pay between 3.2% and 6.7% in dividends.
These stocks pay between 3.2% and 6.7% in dividends.
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game.
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.
If you want to outperform the S&P 500, consider these undervalued dividend stocks for juicy yields and high total return potential.
These income stocks look like good options at current levels.
The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The future of the U.S. economy appears promising, with robust growth and strong...
The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect.
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF?